(288 days)
When used as a cervical intervertebral body fusion device, the Ackermann Intervertebral Body Fusion Device cispine implants are indicated for spinal fusion procedures in skeletally mature patients. Cervical interbody fusion implants are intended for use at one level in the cervical spine, from C2 to T1, for treatment of cervical degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radies). The cervical device is intended to be used in patients who have had six weeks of non-operative treatment. Additionally, the clspine implants are to be used with autogenous bone graft and supplemental fixation via an open, anterior approach.
When used as a lumbar intervertebral body fusion device, the Ackermann Intervertebral Body Fusion Device tispine implants are indicated for spinal fusion procedures in skeletally mature patients. Lumbar interbody fusion implants are intended for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for treatment of lumbar degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The lumbar device is intended to be used in patients who have had six months of non-operative treatment. The tlspine implants may be implanted via an open or a minimally invasive posterior approach. Alternatively, these implanted via a transforaminal approach. These implants are to be used with autogenous bone graft and supplemental fixation.
Ackermann Intervertebral Body Fusion Device c|spine and t|spine is an intervertebral body fusion device that is implanted into the vertebral body space to improve stability of the spine while supporting fusion. Components are offered in a variety of shapes and sizes to meet the requirements of the individual patient anatomy. Components are manufactured from implant grade PEEK (polyetheretherketone, VESTAKEEP® i4 R bv Evonik).
The provided document is a 510(k) summary for a medical device called the "Ackermann Intervertebral Body Fusion Device." This type of submission is for demonstrating substantial equivalence to a legally marketed predicate device, rather than providing detailed clinical study results to establish acceptance criteria for an AI/algorithm-based device.
Therefore, many of the requested points regarding acceptance criteria, specific study designs (like MRMC or standalone performance), sample sizes for test and training sets, and expert ground truth establishment are not applicable to this document as it describes a physical implant device, not an AI or algorithmic diagnostic tool.
However, I can extract the relevant "performance data" which refers to mechanical testing as opposed to clinical or algorithmic performance.
Here's the information that can be extracted from the document:
1. A table of acceptance criteria and the reported device performance
The document refers to adherence to ASTM standards for mechanical testing, which implies the acceptance criteria were defined by these standards. Specific numerical acceptance criteria or reported performance values (e.g., specific load resistance in Newtons) are not detailed in this summary. Instead, it states that the device was "tested in accordance with" specific ASTM standards.
| Acceptance Criteria (Implied by Standard) | Reported Device Performance (Summary) |
|---|---|
| Conformance to ASTM F2077 for static axial compression | Tested in accordance with ASTM F2077 |
| Conformance to ASTM F2077 for dynamic axial compression | Tested in accordance with ASTM F2077 |
| Conformance to ASTM F2077 for static torsion | Tested in accordance with ASTM F2077 |
| Conformance to ASTM F2077 for dynamic torsion | Tested in accordance with ASTM F2077 |
| Conformance to ASTM F2267 for load induced subsidence | Tested in accordance with ASTM F2267 |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
Not applicable. This document describes mechanical testing of a physical device, not an AI/algorithmic device with a "test set" of patient data. The "test set" would refer to the number of physical devices or components tested. This detail is not provided. The manufacturer is Ackermann Instrumente GmbH, located in Rietheim-Weilheim, Germany.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
Not applicable. Ground truth, in the context of AI/algorithms, refers to expert-validated labels. For mechanical testing, the "ground truth" is adherence to ISO/ASTM standards and physical measurements, not expert consensus.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable. Adjudication methods are relevant for resolving discrepancies in expert labeling for AI/algorithm ground truth.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No. This is a physical medical device, not an AI algorithm. Therefore, an MRMC study is not relevant to this submission.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
No. This is a physical medical device.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
Not applicable. The "ground truth" for a physical device's performance is objective measurement based on mechanical testing standards (ASTM F2077, ASTM F2267).
8. The sample size for the training set
Not applicable. This is not an AI/algorithmic device, so there is no "training set."
9. How the ground truth for the training set was established
Not applicable. There is no "training set" for this physical device.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and features the department's name around the perimeter. In the center is an abstract image of a bird-like figure, composed of three human profiles facing to the right.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 16, 2015
Ackermann Instrumente GmbH % Mr. Frank Ferguson Chief Executive Officer Ferguson Medical International Device Consultants, LLC 332 Laskin Road, Suite 437 Virginia Beach, Virginia 23451
Re: K143450
Trade/Device Name: Ackermann Intervertebral Body Fusion Device Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX, ODP Dated: August 14, 2015 Received: August 17, 2015
Dear Mr. Ferguson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
{1}------------------------------------------------
Page 2 - Mr. Frank Ferguson
forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K143450
Device Name
Ackermann Intervertebral Body Fusion Device
Indications for Use (Describe)
When used as a cervical intervertebral body fusion device, the Ackermann Intervertebral Body Fusion Device cispine implants are indicated for spinal fusion procedures in skeletally mature patients. Cervical interbody fusion implants are intended for use at one level in the cervical spine, from C2 to T1, for treatment of cervical degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radies). The cervical device is intended to be used in patients who have had six weeks of non-operative treatment. Additionally, the clspine implants are to be used with autogenous bone graft and supplemental fixation via an open, anterior approach.
When used as a lumbar intervertebral body fusion device, the Ackermann Intervertebral Body Fusion Device tispine implants are indicated for spinal fusion procedures in skeletally mature patients. Lumbar interbody fusion implants are intended for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for treatment of lumbar degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The lumbar device is intended to be used in patients who have had six months of non-operative treatment. The tlspine implants may be implanted via an open or a minimally invasive posterior approach. Alternatively, these implanted via a transforaminal approach. These implants are to be used with autogenous bone graft and supplemental fixation.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
finest surgical technology
Ackermann®
510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR Part 807.92 for the Ackermann Medical Intervertebral Body Fusion Device c|spine and t|spine implants.
DATE PREPARED: 13 August 2015
APPLICANTS NAME AND ADDRESS:
Ackermann Instrumente GmbH Attn: Rolf Ackermann, CEO Eisenbahnstrasse 65-67 78604 Rietheim-Weilheim Germanv Phone: +49 7461 966170; FAX: +49 7461 9661770 RA@Ackermanninstrumente.de
APPLICANTS CONTACT PERSON IN THE USA:
Ferguson Medical International Device Consultants LLC Attn: Frank Ferguson, CEO 332 Laskin Road Suite 437 Virginia Beach, VA 23451 Phone: 757.286.4383; FAX: 801.749.0451 frankf@fergusonmedical-idc.com
{4}------------------------------------------------
DEVICE NAME:
Trade Name: Ackermann Intervertebral Body Fusion Device Common Name: Intervertebral Body Fusion Device Classification Name: Intervertebral Body Fusion Device, 21 CFR 888.3080 Product Code: MAX, ODP
LEGALLY MARKETED DEVICES TO WHICH ACKERMANN IS CLAIMING SUBSTANTIAL EQUIVALENCE:
Primary Predicate Device: Amedica Valeo II Interbody Fusion Device (K142347) Additional Predicate Devices: Aesculap CeSpace PEEK Spinal Implant System (K083311) and Aesculap PEEK Spinal Implant System (K071983)
DEVICE DESCRIPTION:
Ackermann Intervertebral Body Fusion Device c|spine and t|spine is an intervertebral body fusion device that is implanted into the vertebral body space to improve stability of the spine while supporting fusion. Components are offered in a variety of shapes and sizes to meet the requirements of the individual patient anatomy. Components are manufactured from implant grade PEEK (polyetheretherketone, VESTAKEEP® i4 R bv Evonik).
INTENDED USE:
When used as a cervical intervertebral body fusion device, the Ackermann Intervertebral Body Fusion Device c|spine implants are indicated for spinal fusion procedures in skeletally mature patients. Cervical interbody fusion implants are intended for use at one level in the cervical spine, from C2 to T1, for treatment of cervical degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies). The cervical device is intended to be used in patients who have had six weeks of non-operative treatment. Additionally, the c|spine implants are to be used with autogenous bone graft and supplemental fixation via an open, anterior approach.
When used as a lumbar intervertebral body fusion device, the Ackermann Intervertebral Body Fusion Device t|spine implants are indicated for spinal fusion procedures in skeletally mature patients. Lumbar interbody fusion implants are intended for use at either one level or two contiquous levels in the lumbar spine, from L2 to S1, for treatment of lumbar degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of
{5}------------------------------------------------
the disc confirmed by history and radiographic studies. The lumbar device is intended to be used in patients who have had six months of non-operative treatment. The t|spine implants may be implanted via an open or a minimally invasive posterior approach. Alternatively, these implants may be implanted via a transforaminal approach. These implants are to be used with autogenous bone graft and supplemental fixation.
SUMMARY OF THE TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE COMPARED TO THE PREDICATE DEVICE:
The components of the Ackermann Intervertebral Body Fusion Device c|spine and t|spine implants are offered in the same general range of sizes and shapes of the predicate devices. The material used for the Ackermann device is the same as that used to manufacture the reference predicate.
PERFORMANCE DATA:
The Ackermann Intervertebral Body Fusion Device c|spine implants were tested for static axial compression, dynamic axial compression, static torsion, and dynamic torsion in accordance with ASTM 2077 and for load induced subsidence in accordance with ASTM 2267. The t|spine implants were tested for static axial compression and dynamic axial compression in accordance with ASTM 2077 and for load induced subsidence in accordance with ASTM 2267.
CONCLUSIONS:
Based upon the testing and comparison to the predicate device, the Ackermann Intervertebral Body Fusion Device c|spine and t|spine implants have the same intended use and similar technological characteristics. Therefore, the device is substantially equivalent to other legally marketed devices.
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.